Pyxis Oncology, Inc.
Close on Oct 19, 2026
- Market cap
- $112.63M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 2, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | Before market open | – | $-0.40 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | Before market open | – | $-0.37 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 23, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 3, 2025 | Before market open | – | $-0.35 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | After market close | $2.80M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | Before market open | – | $-0.35 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 18, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | – | $-0.35 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 21, 2024 | Before market open | – | – | – |
Press releases
Announcements Pyxis Oncology filed with the SEC
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Pyxis Oncology MICVO Clinical Update September 9, 2026 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
Results of operations · EX-99.1 to Form 8-K
Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
Results of operations · EX-99.1 to Form 8-K
Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Building a Differentiated ADC Company Nasdaq: PYXS March 2026 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Pyxis Oncology MICVO R/M HNSCC Clinical Update December 2025 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Building a Differentiated ADC Company Nasdaq: PYXS May 2025 Exhibit 99.2
Results of operations · EX-99.2 to Form 8-K
Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Building a Differentiated ADC Company Nasdaq: PYXS May 2025 Exhibit 99.2
Results of operations · EX-99.2 to Form 8-K
Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Building a Differentiated ADC Company Nasdaq: PYXS May 2025 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Building a Differentiated ADC Company Nasdaq: PYXS March 2025 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Building a Differentiated ADC Company Nasdaq: PYXS March 18, 2025 Exhibit 99.2
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
Other events · EX-99.1 to Form 8-K
Pyxis Oncology Initiates New PYX-201 Combination Trial and
Other events · EX-99.1 to Form 8-K
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
Other events · EX-99.1 to Form 8-K
PYX-201 Phase 1 Dose Escalation Study Data Disclosure November 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
Regulation FD disclosure · EX-99.2 to Form 8-K
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024
Results of operations · EX-99.1 to Form 8-K
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024
Results of operations · EX-99.1 to Form 8-K
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
Results of operations · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Other events · EX-99.1 to Form 8-K
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
Other events · EX-99.1 to Form 8-K
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Building a Leading ADC-Focused Company Nasdaq: PYXS March 2024 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Pyxis Oncology Announces $50 Million Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Pyxis Oncology Successfully Completes Acquisition of Apexigen
Acquisition or disposition completed · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Pyxis Oncology Reports Financial Results for Second-Quarter 2023
Results of operations · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Other events · EX-99.1 to Form 8-K
Pyxis Oncology Acquisition of Apexigen Nasdaq: PYXS May 24, 2023 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Pyxis Oncology to Acquire Apexigen
Material agreement · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K